J-STAGE Home  >  Publications - Top  > Bibliographic Information

Journal of Hematopoietic Cell Transplantation
Vol. 6 (2017) No. 4 p. 146-151

Language:

http://doi.org/10.7889/hct-17-013

Review

 Inflammatory cytokines play an important role in the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. However, blocking a single cytokine fails to improve the dismal prognosis of patients with GVHD. Jak inhibitors block the signaling of many cytokines relevant to GVHD. Retrospective studies suggest that Jak1/2 inhibitor ruxolitinib could be effective in patients with steroid-refractory GVHD, but has adverse effects such as cytopenia, susceptibility to infection, and withdrawal syndrome. Currently, prospective studies evaluating the efficacy of ruxolitinib and a selective Jak1 inhibitor are in progress.

Copyright © 2017 The Japan Society for Hematopoietic Stem Cell Transplantation

Article Tools

Share this Article